Despite the interesting topic, no data are available on the application of PD/PD-L1 blockage to prevent NAFLD progression to NASH or fibrosis, whereas immunotherapy and in particular the immune checkpoint blockade of PD-1/PD-L1, has been experimented in the treatment of HCC. This evidence concerns the gene PDCD1 and metabolic dysfunction-associated steatotic liver disease.